BeOne Medicines (BEIGF) Cash from Investing Activities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Cash from Investing Activities data on file, last reported at -$45.5 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$45.5 million, up 62.68% year-over-year; the trailing twelve-month figure through Mar 2026 was -$199.7 million (up 56.63% YoY), and the FY2025 annual result was -$276.2 million, up 49.64% from the prior year.
• Cash from Investing Activities eased to -$45.5 million in Q1 2026 per BEIGF's latest filing, from -$38.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $658.7 million in Q2 2022 and troughed at -$209.8 million in Q1 2024.
• A 5-year average of $15.7 million and a median of -$49.3 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 1512.96% in 2022, then tumbled 263.76% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $38.5 million in 2022, then sank by 262.4% to -$62.6 million in 2023, then slumped by 49.57% to -$93.6 million in 2024, then jumped by 59.05% to -$38.3 million in 2025, then retreated by 18.72% to -$45.5 million in 2026.
• Business Quant data shows BEIGF's Cash from Investing Activities at -$45.5 million in Q1 2026, -$38.3 million in Q4 2025, and -$49.3 million in Q3 2025.